Search results for "ANTIRETROVIRAL THERAPY"

showing 10 items of 79 documents

Epstein Barr Virus detection and latent membrane protein 1 in oral hairy leukoplakia in HIV+ Venezuelan patients

2008

Purpose: To determine the prevalence of Epstein Barr Virus (EBV) in oral hairy leukoplakia lesions (OHL) in HIV+ Venezuelan patients. Material and Method: In this case study, we evaluated 21 HIV+ adult patients with clinically present OHL lesions, 11 who were undergoing antiretroviral therapy, 10 who were not undergoing therapy and 10 HIV-negative adult patients with hyperkeratotic oral mucosal lesions. All of the subjects were assessed at the Infectious Disease Center, Faculty of Dentistry, Central University of Venezuela, and were clinically examined to detect oral mucosal lesions with the confirmed histopathologic diagnosis. Nested-PCR was used to determine the EBV infection and the late…

AdultMaleHerpesvirus 4 HumanLeukoplakia HairyHuman immunodeficiency virus (HIV)medicine.disease_causeViral Matrix ProteinsYoung Adulthemic and lymphatic diseasesHIV SeropositivityHumansMedicineYoung adultGeneral DentistryLeukoplakiaOral hairy leukoplakiabusiness.industryMiddle AgedVenezuela:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseAntiretroviral therapyEpstein–Barr virusOtorhinolaryngologyInfectious disease (medical specialty)UNESCO::CIENCIAS MÉDICASImmunologyImmunohistochemistryFemaleSurgerybusinessMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Vaccination Against Hepatitis B Virus (HBV) in HIV-1-Infected Patients With Isolated Anti-HBV Core Antibody: The ANRS HB EP03 CISOVAC Prospective Stu…

2016

International audience;  Although an isolated anti-hepatitis B virus (HBV) core antibody (anti-HBc) serological profile is frequent in human immunodeficiency virus (HIV)-infected patients, data on HBV vaccination in these patients are scarce.  A prospective multicenter study was conducted to assess the immunogenicity of HBV vaccination in 54 patients with an isolated anti-HBc profile and undetectable HIV load. They were vaccinated with 1 dose (20 µg) of recombinant HBV vaccine. Those with an anti-HBV surface antibody (anti-HBs) level of 100 mIU/mL 4 weeks after a single recall dose of HBV vaccine should be further vaccinated with a reinforced triple double-dose scheme.

AdultMaleHuman immunodeficiency virus (HIV)HIV Infectionsmedicine.disease_causeVirusSerology03 medical and health sciences0302 clinical medicineImmunogenicity Vaccine[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyAntiretroviral Therapy Highly ActiveHepatitis B virus HBVImmunology and AllergyMedicineHumansHepatitis B Vaccines030212 general & internal medicineProspective StudiesHepatitis B AntibodiesProspective cohort study[SDV.MP] Life Sciences [q-bio]/Microbiology and ParasitologyVaccines Syntheticbiologybusiness.industryImmunogenicityvirus diseasesMiddle AgedHepatitis BVirologyHepatitis B Core Antigensdigestive system diseasesVaccinationInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyImmunologybiology.proteinHIV-1030211 gastroenterology & hepatologyFemaleAntibodybusiness
researchProduct

Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010

2012

Prevalence and predictors of transmitted drug resistance (TDR), defined as the presence of at least one WHO surveillance drug resistance mutation (SDRM), were investigated in antiretroviral-naïve HIV-1-infected patients, with a genotypic resistance test (GRT) performed ≤6months before starting cART between 2000 and 2010. 3163 HIV-1 sequences were selected (69% subtype B). Overall, the prevalence of TDR was 12% (13.2% subtype B, 9% non-B). TDR significantly declined overall and for the single drug classes. Older age independently predicted increased odds of TDR, whereas a more recent GRT, a higher HIV-RNA and C vs. B subtype predicted lower odds of TDR. © 2012 The Authors. Clinical Microbiol…

AdultMaleMicrobiology (medical)CartDrugmedicine.medical_specialtyGenotypeAnti-HIV Agentsmedia_common.quotation_subjectHuman immunodeficiency virus (HIV)HIV InfectionsDrug resistancemedicine.disease_causeArticleEvolution Molecular03 medical and health sciencesrecent HIV infection0302 clinical medicineInternal medicineDrug Resistance ViralPrevalencemedicineHumansHIV Infection030212 general & internal medicinemedia_common0303 health scienceschronic HIV infection030306 microbiologybusiness.industryAntiretroviral therapy; Chronic HIV infection; Recent HIV infection; Resistance epidemiology; Transmitted resistance; Microbiology (medical); Infectious DiseasesAnti-HIV AgentGeneral MedicineMiddle Agedtransmitted resistanceVirologyAntiretroviral therapy3. Good healthAntiretroviral therapyInfectious DiseasesItalyHIV-1Genotypic resistanceFemalebusinessHumanresistance epidemiologyClinical Microbiology and Infection
researchProduct

Effect of highly active anti-retroviral therapy and hepatitis C virus co-infection on serum levels of pro-inflammatory and immunoregulatory cytokines…

2006

ABSTRACTThis study aimed to determine the effect of highly active anti-retroviral therapy (HAART) and hepatitis C virus (HCV) co-infection on peripheral levels of interleukin (IL)-2, IL-10, IL-12 (p70), IL-18 and soluble tumour necrosis factor receptor type II (sTNFRII). Serum levels were monitored for a 1-year period in 25 patients infected with human immunodeficiency virus-1 (HIV-1) who were naive for HAART at the initiation of the study, and in four HIV-1-infected long-term non-progressors. Serum levels of both IL-18 and sTNFRII at baseline were significantly higher in HIV-1-infected patients than in controls. Baseline levels of IL-18 and sTNFRII were not significantly different in long-…

AdultMaleMicrobiology (medical)hepatitis C virusTime FactorsHAARTHepatitis C virusHepacivirusHIV Infectionsmedicine.disease_causeserum cytokinesReceptors Tumor Necrosis FactorVirusEtanerceptAntiretroviral Therapy Highly ActiveImmunopathologymedicineHumansLongitudinal StudiesDemographybiologyhuman immunodeficiency virusbusiness.industryInterleukinsInterleukinvirus diseasesGeneral MedicineHepatitis Csoluble tumour necrosis factor receptor type IIMiddle Agedmedicine.diseasebiology.organism_classificationHepatitis CInfectious DiseasesImmunoglobulin GImmunologyLentivirusHIV-1CytokinesFemaleViral diseasebusinessIL-18Clinical Microbiology and Infection
researchProduct

Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial inf…

2008

Background. Because of the known relationship between exposure to combination antiretroviral therapy and cardiovascular disease (CVD), it has become increasingly important to intervene against risk of CVD in human immunodeficiency virus (HIV)-infected patients. We evaluated changes in risk factors for CVD and the use of lipid-lowering therapy in HIV-infected individuals and assessed the impact of any changes on the incidence of myocardial infarction. Methods. The Data Collection on Adverse Events of Anti-HIV Drugs Study is a collaboration of 11 cohorts of HIV-infected patients that included follow-up for 33,389 HIV-infected patients from December 1999 through February 2006. Results. The pro…

AdultMaleMicrobiology (medical)medicine.medical_specialtyAnti-HIV AgentsImmunologyantiretroviral therapyMyocardial Infarction610 Medicine & healthHIV Infections2726 Microbiology (medical)Article10234 Clinic for Infectious DiseasesCoronary artery diseasecardiovascular diseaselipidDiabetes mellitusInternal medicinemedicineHumansHIV InfectionMyocardial infarctionAdverse effectHypolipidemic AgentsHypolipidemic Agentbusiness.industryIncidenceIncidence (epidemiology)Anti-HIV AgentHIV2725 Infectious DiseasesMiddle Agedmedicine.diseaseConfidence intervalSurgeryInfectious DiseasesFemalebusinessBody mass indexDyslipidemiaHuman
researchProduct

Reversible posterior leukoencephalopathy secondary to indinavir-induced hypertensive crisis: A case report

2002

Reversible posterior leukoencephalopathy syndrome (RPLS) is an uncommon entity related to multiple and different pathologies, the most common being hypertensive crisis. It is believed to be secondary to the breakdown on the blood-brain barrier. At the beginning, it is undistinguishable from other leukoencephalopathies. However, the disappearance of brain lesions after removal of the potential cause, establish the differential diagnosis with other leukoencephalopathies. We present the case of an HIV-infected patient with a RPLS related to a hypertensive crisis short after the initiation of indinavir-containing highly active antiretroviral therapy. Once blood pressure was controlled and indin…

AdultMalePathologymedicine.medical_specialtyHypertensive encephalopathymedicine.medical_treatmentHIV InfectionsIndinavirIndinavirAntiretroviral Therapy Highly ActiveHypertensive EncephalopathyInternal MedicinemedicineHumansChemotherapymedicine.diagnostic_testbusiness.industryProgressive multifocal leukoencephalopathyvirus diseasesMagnetic resonance imagingHIV Protease Inhibitorsmedicine.diseaseMagnetic Resonance ImagingHyperintensityNelfinavirDifferential diagnosisbusinessmedicine.drugAmerican Journal of Hypertension
researchProduct

Detection of HIV type 1 non-B subtypes in Sicily, Italy.

2004

To evaluate the presence of HIV-1 non-B subtypes in Sicily, we sequenced and genotyped HIV-1 PR and RT regions of the pol gene using plasma from 169 HIV-1-infected adult patients. All samples were obtained from a study of antiretroviral-associated resistance mutations resulting in virological failure during highly active antiretroviral therapy (HAART). Eight (4.7%) patients had the non-B HIV-1 subtype including some circulating recombinant forms (CRFs). All of these individuals acquired the infection by heterosexual transmission. The detection of HIV-1 non-B strains was significantly associated with younger age of HIV-1 acquisition. Our findings indicate, for the first time, the presence of…

AdultMalePol genesYounger ageImmunologyMolecular Sequence DataHuman immunodeficiency virus (HIV)HIV Infectionsmedicine.disease_causeVirusVirologyAntiretroviral Therapy Highly ActiveDrug Resistance ViralmedicineHumansIn patientTreatment FailurebiologyAdult patientsvirus diseasesMiddle Agedbiology.organism_classificationAntiretroviral therapyVirologyGenes polInfectious DiseasesItalyLentivirusImmunologyMutationHIV-1RNA ViralFemaleAIDS research and human retroviruses
researchProduct

Genetic Diversity of HIV-1 Non-B Strains in Sicily: Evidence of Intersubtype Recombinants by Sequence Analysis ofgag,pol, andenvGenes

2007

The molecular epidemiology of HIV-1 strains in Sicily (Italy) was phylogenetically investigated by the analysis of HIV-1 gag, pol, and env gene sequences from 11 HIV-1 non-B strains from 408 HIV-1-seropositive patients observed from September 2001 to August 2006. Sequences suggestive of recombination were further investigated by bootscanning analysis of various fragments. Overall, we identified several second-generation recombinant (SGRs) strains, which contained genetic material of CRF02_AG in at least one gene. Notably, three individuals were found to be infected with subsubtype A3, and one of them showed genetic recombination with subsubtype A4. The current study emphasizes the genetic a…

AdultMaleSUBTYPE-ASequence analysisMolecular Sequence DataImmunologyGene Products gagGene Products polHIV InfectionsBiologySettore MED/42 - Igiene Generale E ApplicataGenetic recombinationGenetic analysisCRF02-AGlaw.inventionSUPERINFECTIONANTIRETROVIRAL THERAPYMOLECULAR EPIDEMIOLOGYlawVirologyHumansPHYLOGENETIC ANALYSISSicilyGeneWEST-AFRICAAgedRecombination GeneticGeneticsGenetic diversityCOMPLEXMolecular epidemiologyStrain (biology)Gene Products envGenetic Variationvirus diseasesSequence Analysis DNAMiddle AgedIMMUNODEFICIENCY-VIRUS TYPE-1VirologyInfectious DiseasesHIV-1CAMEROONRecombinant DNAFemaleAIDS Research and Human Retroviruses
researchProduct

Metabolic syndrome and body weight in people living with HIV infection: analysis of differences observed in three different cohort studies over a dec…

2022

Objectives: The aim of this study was to assess the incidence of being overweight and metabolic syndrome (MS) among people living with HIV (PHIV) in three different cross-sectional studies conducted over three different periods: 2005, 2011 and 2015. Methods: This was a multi-centre, nationwide study. Data were collected in three studies from the CISAI group - SIMOne, HIV-HY and STOPSHIV - and included a total of 3014 PHIV. Logistic regression [odds ratio (OR), 95% confidence interval (CI)] was used to account for age and gender difference among three groups when comparing MS prevalence and being overweight; potential confounders were accounted for by including them in the regression equatio…

AdultMaledyslipidaemiaantiretroviral therapyHIV InfectionsOverweightLogistic regressionBody Mass IndexCohort StudiesPrevalencemedicineoverweightHumansPharmacology (medical)Metabolic Syndromebusiness.industryHealth PolicyIncidence (epidemiology)Body WeightHIVweight gainOdds ratioMiddle Agedmedicine.diseaseConfidence intervalHIV; antiretroviral therapy; dyslipidaemia; metabolic syndrome; overweight; weight gainCross-Sectional StudiesInfectious Diseasesweight gain.Metabolic syndromemedicine.symptombusinessWeight gainDemographyCohort studyHIV Medicine
researchProduct

Transmission of Drug-Resistant HIV Type 1 Strains in HAART-Naive Patients: A 5-Year Retrospective Study in Sicily, Italy

2010

The transmission of drug-resistant HIV-1 strains might compromise the efficacy of current first-line antiretroviral (ARV) regimens. Between 2004 and 2008, HIV-1 reverse transcriptase (RT) and protease (PR) genes of 108 ARVnaive Sicilian patients were amplified and sequenced to describe the prevalence of ARV resistance mutations among HAART-naive HIV-1-infected individuals. The frequency of transmitted drug resistance mutations (DRAMs) was determined by using genotypic interpretation algorithms. The proportion of HAART-naive HIV- 1-infected patients in Sicily increased from 18.4% to 23.5% during 2004–2008. Among naive patients, the overall prevalence of DRAMs was 15.7% [17/108; 95% CI: 9.4–2…

AdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentMolecular Sequence DataImmunologyHIV InfectionsDrug resistanceSettore MED/42 - Igiene Generale E ApplicataVirusYoung AdultAntiretroviral Therapy Highly ActiveVirologyMolecular geneticsDrug Resistance ViralGenotypePrevalencemedicineHumansChildSicilyAgedRetrospective StudiesHAART-naive HIV-1 drug resistanceProteaseMolecular epidemiologybiologyInfantvirus diseasesHIV Protease InhibitorsMiddle Agedbiology.organism_classificationVirologyReverse transcriptaseInfectious DiseasesChild PreschoolMutationLentivirusHIV-1Reverse Transcriptase InhibitorsFemaleAIDS Research and Human Retroviruses
researchProduct